Swiss biotech companies: R & D expenses 2016-2018

This statistic show Swiss biotech companies' research and development expenses from 2016 to 2018. In 2016, Swiss biotech companies invested a total of around 1.14 billion Swiss francs into research and development.

Swiss biotech and pharma companies

Swiss biotech companies have increased their research and development (R&D) expenses in recent years, from 1.12 billion Swiss francs in 2015 to 1.39 billion Swiss francs in 2017. The amounts spent by public and private companies were around 568 and 823 million francs, respectively. There are some 240 Swiss companies that use biotechnological technologies to develop products. Many are located around Lake Geneva, the Greater Basel Area, and the Greater Zurich Area.

Swiss company Novartis is one of the world’s largest pharmaceutical companies based on prescription sales, generating 49 billion U.S. dollars in 2017, in comparison, research and development spending totaled about 8.3 billion U.S. dollars. Novartis was established in 1996 when the companies, Ciba-Geigy and Sandoz Laboratories, were merged. Currently, the company is headquartered in Basel and its campus includes works from a variety of artists and architects. Novartis revenues are dominated by its pharmaceutical segment, receiving 33 billion U.S. dollars in 2017, and in comparison, it garnered 6 billion U.S. dollars in the Alcon segment.

Roche, another Swiss company, generated 41.7 billion U.S. dollars from pharmaceutical prescription sales and expended 9.2 billion U.S. dollars on R&D in 2017.

Swiss biotech companies' research and development expenses from 2016 to 2018 (in million Swiss francs)*

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

May 2019



Survey time period

2016 to 2018

Supplementary notes

* As some privately held companies do not disclose financial figures, the figures above represent EY’s best estimate. All figures are headquarter-counted and do not include data from pharma companies such as Novartis and Roche.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical trends in Europe"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.